EpiCast Report 2016: Vasculitis - Epidemiology Forecast to 2024 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hlbbss/epicast_report) has announced the addition of the "EpiCast Report: Vasculitis - Epidemiology Forecast to 2024" report to their offering.

Vasculitis is a group of heterogeneous disorders affecting persons of both sexes and all ages. These disorders are characterized by inflammation and necrosis of the blood vessels including the veins, arteries, and capillaries. There are various forms of vasculitis, and their clinical expressions may differ greatly in terms of symptoms observed, severity and duration of the disease depending on disease site and type of blood vessels involved.

Scope

- The Vasculitis EpiCast Report provides an overview of the risk factors and global trends of selected vasculitis disorders in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The selected vasculitis disorders are anti-neutrophil cytoplasmic antibod-associated vasculitis (AAV) (microscopic polyangitis [MPA], granulomatosis with polyangitis [GPA], and eosinophilic granulomatosis with polyangitis [eGPA]), large vessel vasculitis (LVV) (giant cell arteritis [GCA] and Takayasu's arteritis [TA]), Beh├žet's disease (BD), and Kawasaki disease (KD). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of AAV, LVV, BD, and KD, as well as the diagnosed prevalent cases of AAV, TA, and BD. Age and sex segmentations are also provided.

- The vasculitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global Trends

3.4 Forecast Methodology

3.5 Epidemiological Forecast for Vasculitis, 2014-2024

3.5.1 Diagnosed Incident Cases of AAV

3.5.2 Diagnosed Prevalent Cases of AAV

3.5.3 Age-Standardized Incidence of AAV

3.5.4 Diagnosed Incident Cases of LVV - TA and GCA

3.5.5 Diagnosed Prevalent Cases of TA

3.5.6 Age-Standardized Incidence of LVV

3.5.7 Diagnosed Incident Cases of BD

3.5.8 Diagnosed Prevalent Cases of BD

3.5.9 Age-Standardized Incidence of BD

3.5.10 Diagnosed Incident Cases of KD

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

For more information visit http://www.researchandmarkets.com/research/hlbbss/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular